HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Cardiff Oncology (NASDAQ:CRDF) and maintained a $14 price target. This reaffirms the firm's positive outlook on the stock.
May 06, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Cardiff Oncology with a $14 price target, indicating a strong positive outlook.
The reiteration of a Buy rating and maintenance of a $14 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an uptick in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100